A Study of EP0031 in Patients With Advanced RET-altered Malignancies

Trial ID or NCT#

NCT05443126

Status

recruiting iconRECRUITING

Purpose

The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies

Official Title

A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0031 in Patients With Advanced RET-altered Malignancies

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Saad A. Khan, MD
Saad A. Khan, MD
Medical oncologist
Associate Professor of Medicine (Oncology)

Contact us to find out if this trial is right for you.

Contact

Emmanuel Ifeanyi Ugwu

SEND MESSAGE

View on ClinicalTrials.gov